Progressive multifokale Leukenzephalopathie

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Der Nervenarzt

• Publication date

  2016-10-11

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s00115-016-0225-7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of immune escape in central nervous system infection with neurotropic JC virus variant

  2016cited by this paper
• Disease-modifying therapies and infectious risks in multiple sclerosis

  2016cited by this paper
• CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

  2016cited by this paper
• Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF

  2015cited by this paper
• JC polyomavirus mutants escape antibody-mediated neutralization

  2015cited by this paper
• Progressive multifocal leukoencephalopathy: current treatment options and future perspectives

  2015cited by this paper
• Lipid‐specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

  2015cited by this paper
• Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

  2015cited by this paper
• Broadly neutralizing human monoclonal JC polyomavirus VP1–specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy

  2015cited by this paper
• JC Virus Quasispecies Analysis Reveals a Complex Viral Population Underlying Progressive Multifocal Leukoencephalopathy and Supports Viral Dissemination via the Hematogenous Route

  2014cited by this paper
• JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.

  2014cited by this paper
• Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?

  2014cited by this paper
• Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab‐associated progressive multifocal leukoencephalopathy

  2014cited by this paper
• JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants

  2014cited by this paper
• Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

  2014cited by this paper
• The CSF JCV antibody index for diagnosis of natalizumab-associated PML

  2014cited by this paper
• Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

  2014cited by this paper
• Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

  2014cited by this paper
• MRI pattern in asymptomatic natalizumab-associated PML

  2014cited by this paper
• Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.

  2014cited by this paper
• l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

  2013cited by this paper
• JC virus granule cell neuronopathy and GCN–IRIS under natalizumab treatment

  2013cited by this paper
• Changes to anti-JCV antibody levels in a Swedish national MS cohort

  2013cited by this paper
• PML diagnostic criteria

  2013cited by this paper
• Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathy

  2012cited by this paper
• Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain

  2012cited by this paper
• Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

  2012cited by this paper
• Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis

  2011cited by this paper
• Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient

  2011cited by this paper
• Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS

  2011cited by this paper
• Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.

  2011cited by this paper
• JC virus viremia in interferon-β-treated and untreated Italian multiple sclerosis patients and healthy controls

  2011cited by this paper
• CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

  2011cited by this paper
• Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?

  2010cited by this paper
• Steroids for PML-IRIS

  2009cited by this paper
• PML-IRIS in patients with HIV infection

  2009cited by this paper
• Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA

  2009cited by this paper
• Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

  2009cited by this paper
• Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases.

  2009cited by this paper
• Adaptive Mutations in the JC Virus Protein Capsid Are Associated with Progressive Multifocal Leukoencephalopathy (PML)

  2009cited by this paper
• The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.

  2008cited by this paper
• Detection of JC virus DNA fragments but not proteins in normal brain tissue

  2008cited by this paper
• Influence of HAART on the Clinical Course of HIV-1-Infected Patients With Progressive Multifocal Leukoencephalopathy: Results of an Observational Multicenter Study

  2008cited by this paper
• Internally Controlled Triplex Quantitative PCR Assay for Human Polyomaviruses JC and BK

  2008cited by this paper
• Occurrence rate and genotype distribution of the JC virus (JCV) in a sample from the Polish population

  2008cited by this paper
• Response to Linberg et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.

  2008cited by this paper
• Is detection of JC virus DNA in blood a valuable screening test for progressive multifocal leukoencephalopathy in Crohn's disease patients eligible for anti-alpha4 integrin therapy?

  2008cited by this paper
• False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing.

  2008cited by this paper
• Progressive multifocal leukoencephalopathy – the importance of early diagnosis illustrated in four cases

  2008cited by this paper
• The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.

  2008cited by this paper
• Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature

  2008cited by this paper
• Update on PML: Lessons from the HIV uninfected and new insights in pathogenesis and treatment

  2008cited by this paper
• Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

  2008cited by this paper
• Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose

  2008cited by this paper
• Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis

  2008cited by this paper
• POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS

  2008cited by this paper
• JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?

  2008cited by this paper
• Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.

  2008cited by this paper
• Plasma exchange augments leukocyte transmigration across an in vitro blood-brain barrier in natalizurnab-treated patients with multiple sclerosis

  2008cited by this paper
• TNFα blockade in human diseases : An overview of efficacy and safety

  2008cited by this paper
• Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

  2008cited by this paper
• Potential Mechanisms of the Human Polyomavirus JC in Neural Oncogenesis

  2008cited by this paper
• Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.

  2007cited by this paper
• PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY AFTER RITUXIMAB IN A CASE OF NON-HODGKIN LYMPHOMA

  2007cited by this paper
• Reactivation of JC virus and development of PML in patients with multiple sclerosis

  2007cited by this paper
• Health‐related quality of life in multiple sclerosis: effects of natalizumab

  2007cited by this paper
• Natalizumab for multiple sclerosis.

  2007cited by this paper
• Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.

  2007cited by this paper
• JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event

  2007cited by this paper
• The effect of plasma exchange in accelerating clearance of natalizumab in patients with multiple sclerosis: results of the PLEX study

  2007cited by this paper
• Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.

  2007cited by this paper
• Pharmacotherapeutic options for the management of human polyomaviruses.

  2006cited by this paper
• Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

  2006cited by this paper
• Analysis of the transcriptional control region of JC polyomavirus in cerebrospinal fluid from HIV‐negative patients with progressive multifocal leucoencephalopathy

  2006cited by this paper
• Natalizumab and progressive multifocal leucoencephalopathy

  2006cited by this paper
• Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients

  2006cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

  2006cited by this paper
• Central nervous system infections - a potential complication of systemic immunotherapy.

  2006cited by this paper
• Immune surveillance in multiple sclerosis patients treated with natalizumab

  2006cited by this paper
• Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.

  2006cited by this paper
• Human demyelinating disease and the polyomavirus JCV

  2006cited by this paper
• Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

  2006cited by this paper
• JC virus granule cell neuronopathy: A novel clinical syndrome distinct from progressive multifocal leukoencephalopathy

  2005cited by this paper
• Reduced Rate of Diagnostic Positive Detection of JC Virus DNA in Cerebrospinal Fluid in Cases of Suspected Progressive Multifocal Leukoencephalopathy in the Era of Potent Antiretroviral Therapy

  2005cited by this paper
• Natalizumab and PML

  2005cited by this paper
• Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.

  2005cited by this paper
• Anti-&agr;4 integrin therapy for multiple sclerosis: Mechanisms and rationale

  2005cited by this paper
• Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.

  2005cited by this paper
• Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.

  2005cited by this paper
• Changes in the natural history of progressive multifocal leukoencephalopathy in HIV‐negative lymphoproliferative disorders: Impact of novel therapies

  2005cited by this paper
• A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.

  2004cited by this paper
• Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits.

  2004cited by this paper
• New insights into progressive multifocal leukoencephalopathy

  2004cited by this paper
• Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid.

  2004cited by this paper
• JC Virus Multiplication in Human Hematopoietic Progenitor Cells Requires the NF-1 Class D Transcription Factor

  2001cited by this paper
• Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals.

  1999cited by this paper
• JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency

  1996cited by this paper
• Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy

  1992cited by this paper

• PML - opportunistische Infektion des Gehirns

  2023cites this paper
• Diagnostische Verfahren

  2020cites this paper
• The Cerebrospinal Fluid in Multiple Sclerosis

  2019cites this paper
• Entzündliche Erkrankungen

  2019cites this paper
• [Progressive multifocal encephalopathy in neurological practice].

  2017cites this paper
• Modellierung von Risiken und Nutzen

  2017cites this paper
• Brain and Spinal Cord MRI in Multiple Sclerosis: an Update

  2017cites this paper
• Das A & O der Liquordiagnostik

  2017cites this paper
• Zerebrale und spinale Bildgebung der Multiplen Sklerose: ein Update

  2017cites this paper